A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Simtuzumab (Primary)
  • Indications Liver cirrhosis
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Oct 2017 Results of a study validating hepatic collagen content for the prediction of clinical disease progression in patients with advanced fibrosis due to NASH using patient data from NCT01672879 and NCT01672866 trials presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results of a study validating enhanced liver fibrosis for prediction of clinical disease progression in patients with NASH and advanced fibrosis using patient data from NCT01672879 and NCT01672866 trials presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results describing variability in hepatic venous pressure gradient measurement using patients data (n=256) from this study, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top